Hematopoietic Stem Cell TransplantationTransplantation, HomologousBone Marrow TransplantationGraft vs Host DiseaseTransplantation ConditioningHematologic NeoplasmsHematopoietic Stem CellsTransplantation, AutologousStem Cell TransplantationTransplantation ChimeraWhole-Body IrradiationTissue DonorsLeukemiaGraft vs Leukemia EffectBusulfanBone MarrowGraft vs Tumor EffectHistocompatibilityHistocompatibility TestingRecurrenceGraft SurvivalBone Marrow CellsAnemia, AplasticTreatment OutcomePeripheral Blood Stem Cell TransplantationLeukemia, Myelogenous, Chronic, BCR-ABL PositiveLeukemia, Myeloid, AcuteRetrospective StudiesRemission InductionLymphocyte TransfusionPrecursor Cell Lymphoblastic Leukemia-LymphomaMyelodysplastic SyndromesMyeloablative AgonistsHematologic DiseasesImmunosuppressive AgentsHepatic Veno-Occlusive DiseaseChimerismAcute DiseaseLymphocyte DepletionHLA AntigensTransplantation, IsogeneicCyclophosphamideCombined Modality TherapyCytomegalovirus InfectionsTime FactorsTransplantation ImmunologyStem CellsSurvival AnalysisT-LymphocytesVidarabineSurvival RateHematopoiesisCord Blood Stem Cell TransplantationAllograftsMice, Inbred C57BLLeukemia, MyeloidLeukocyte TransfusionLiver TransplantationSiblingsDisease-Free SurvivalImmunosuppressionSevere Combined ImmunodeficiencyRadiation ChimeraFollow-Up StudiesMinor Histocompatibility AntigensNeoplasm, ResidualMultiple MyelomaCyclosporineGraft RejectionFatal OutcomeFlow CytometryAntilymphocyte SerumSalvage TherapyGraft vs Host ReactionOpportunistic InfectionsLymphoproliferative DisordersAntigens, CD34Antineoplastic Combined Chemotherapy ProtocolsImmunocompromised HostCytarabineCystitisHematopoietic Stem Cell MobilizationCytomegalovirusPrognosisBone Marrow PurgingLeukemic InfiltrationKidney TransplantationGanciclovirCell DifferentiationChimeraRisk FactorsLymphoma, Non-HodgkinBlood Group IncompatibilityBone and BonesNuclear FamilyMice, Inbred BALB CGranulocyte Colony-Stimulating FactorIsoantigensPrimary MyelofibrosisChronic Disease